Population pharmacokinetic analysis of lanreotide Autogel® in healthy subjects: Evidence for injection interval of up to 2 months

Clinical Pharmacokinetics

Volumn 48, Issue 1, 2009, Pages 51-62

  Trocóniz, Iñaki F ^a   Cendrós, Josep María ^b   Peraire, Concepción ^b   Ramis, Joaquim ^b   Garrido, Maria J ^a   Boscani, Paolo F ^b   Obach, Rosendo ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IPSEN   (France)

Author keywords

Lanreotide, pharmacokinetics; Population pharmacokinetics; Somatotropin receptor antagonists, pharmacokinetics

Indexed keywords

ANGIOPEPTIN; AUTOGEL; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ARTICLE; BILIARY COLIC; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RELEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMEDIATE RELEASE FORMULATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROENDOCRINE TUMOR; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; POPULATION RESEARCH; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; VOMITING;

ADOLESCENT; ADULT; FEMALE; GELS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 57449121822     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/0003088-200948010-00004     Document Type: Article

References (25)

1. Giusti M, Ciccarelli E, Dallabonzana D, et al. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 1997; 27: 277-84
2. Cannavò S, Squadrito S, Curtò L, et al. Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 2000; 32 (6): 224-9
3. Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp Med 2002; 63 (3): 162-5
4. Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol 2005; 63: 514-9
5. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002; 87 (1): 99-104
6. Caron P, Bex M, Cullen DR, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 2004; 60 (6): 734-40
7. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17 (2): 600-6
8. Cendrós J, Peraire C, Trocóniz I, et al. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism 2005; 54: 1276-81
9. Barbanoj M, Antonijoan R, Morte A, et al. Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. Clin Pharmacol Ther 1999; 66 (5): 485-91
10. Vahl N, Moller N, Lauritzen T, et al. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. J Clin Endocrinol Metab 1997; 82: 3612-8
11. NONMEM® user's guides. Beal SL, Sheiner LB, Boeckmann AJ, editors. Ellicott City (MA): Icon Development Solutions, 1989-2006
12. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504
13. Karlsson MO. Handling data below the limit of quantification (BQL) - including simultaneous modeling of continuous and categorical data [lecture]. NONMEM® VI Workshop; 2008 Mar 17-19; San Francisco (CA)
14. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz Criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 1994; 22: 431-45
15. Holford N, Ambros R, Stoeckel K. Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokin Biopharm 1992; 20: 421-42
16. Piotrovskii VK. The use of Weibull distribution to describe the in vivo absorption kinetics. J Pharmacokinet Biopharm 1987; 15: 681-6
17. Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-26
18. Holford N. The visual predictive check: superiority to standard diagnostic (Rorschach) plots [abstract no. 738]. 14th Meeting, Population Approach Group in Europe; 2005 Jun 16-17; Pamplona [online]. Available from URL: http://www.page-meeting.org/default.asp?abstract=738 [Accessed 2008 Oct 6]
19. Ramis J, Cendrós J-M, Catus F, et al. Pharmacokinetics and pharmacodynamics of lanreotide Autogel® after multiple subcutaneous administration in patients with acromegaly: a 52-week, multi-centre, randomized study [poster]. 12th International Congress of Endocrinology; 2004 Aug 31-Sep 4; Lisbon
20. Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2004; 56 (4): 471-6
21. Rowland M, Tozer T. Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia (PA): Williams & Wilkins, 1995
22. Valery C, Paternostre M, Robert B, et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc Natl Acad Sci U S A 2003; 100 (18): 10258-62
23. Valery C, Artzner F, Robert B, et al. Self-association process of a peptide in solution: from beta-sheet filaments to large embedded nanotubes. Biophys J 2004; 86 (4): 2484-501
24. Keller A, Wu Z, Kratzsch J, et al. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Eur J Endocrinol 2007; 156: 647-53
25. Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks Rorin patients with acromegaly previously responsive to lanreotide microparticles, 30 mg: a phase III trial. J Clin Endocrinol Metab 2006; 65: 320-6